Gold prices rise from 2-wk low with focus on Russia-Ukraine, Jackson Hole
Vigil Neuroscience , Inc. (NASDAQ:VIGL) announced Thursday that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its planned merger with Sanofi (NASDAQ:SNY) has expired. According to a statement based on a recent SEC filing, the waiting period ended at 11:59 p.m. Eastern Time on Wednesday. The announcement comes as Vigil’s stock trades near its 52-week high of $8.09, having surged over 318% in the past six months.
The expiration of this waiting period satisfies one of the key conditions required to complete the merger, in which Sanofi, through its subsidiary Vesper Acquisition Sub Inc., will acquire Vigil Neuroscience. Vigil will become a wholly owned subsidiary of Sanofi following the transaction. According to InvestingPro data, Vigil maintains a healthy financial position with more cash than debt and a strong current ratio of 2.97.
The completion of the merger remains subject to other customary closing conditions, including approval by Vigil’s stockholders. A special virtual meeting for stockholders to consider and vote on the adoption of the merger agreement is scheduled for August 4, 2025, at 8:30 a.m. Eastern Time.
Vigil Neuroscience is incorporated in Delaware and is headquartered in Watertown, Massachusetts. The company’s common stock is listed on the Nasdaq Global Select Market under the ticker VIGL.
The information in this article is based on a press release statement contained in Vigil Neuroscience’s SEC filing.
In other recent news, Vigil Neuroscience has decided to discontinue its Phase 2 IGNITE clinical trial for iluzanebart, a treatment candidate for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). The trial was halted because the drug did not meet the expected biomarker or clinical efficacy endpoints, although it showed a favorable safety and tolerability profile. Meanwhile, Vigil Neuroscience is set to be acquired by Sanofi for approximately $470 million, equivalent to $8 per share. This acquisition is anticipated to close in the third quarter of 2025, pending regulatory approvals and stockholder consent. Analysts from Stifel, Mizuho (NYSE:MFG), and Guggenheim have downgraded Vigil Neuroscience’s stock rating to Neutral, aligning their price targets to the acquisition offer of $8 per share. The deal includes a contingent value right (CVR) of $2 per share, contingent upon the commercial success of VG-3927, an investigational treatment for Alzheimer’s disease. At a recent stockholders’ meeting, Vigil’s shareholders approved board nominees and ratified PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2025. The acquisition by Sanofi will not include iluzanebart, which will revert to Amgen (NASDAQ:AMGN), the original licensor.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.